22.23
0.07%
-0.015
Landos Biopharma Inc stock is currently priced at $22.23, with a 24-hour trading volume of 3,863.
It has seen a -0.07% decreased in the last 24 hours and a +3.47% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $22.17 pivot point. If it approaches the $22.44 resistance level, significant changes may occur.
Previous Close:
$22.25
Open:
$22.2912
24h Volume:
3,863
Market Cap:
$69.36M
Revenue:
-
Net Income/Loss:
$-21.94M
P/E Ratio:
-4.6035
EPS:
-4.83
Net Cash Flow:
$-20.48M
1W Performance:
-0.34%
1M Performance:
+3.47%
6M Performance:
+442.32%
1Y Performance:
+7,567%
Landos Biopharma Inc Stock (LABP) Company Profile
Name
Landos Biopharma Inc
Sector
Industry
Phone
540 218 2232
Address
1800 Kraft Drive, Suite 216, Blacksburg
Landos Biopharma Inc Stock (LABP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-12-22 | Downgrade | Jefferies | Buy → Hold |
Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Oct-20-21 | Initiated | Craig Hallum | Buy |
Oct-19-21 | Initiated | H.C. Wainwright | Buy |
Mar-01-21 | Initiated | JP Morgan | Neutral |
Mar-01-21 | Initiated | Jefferies | Buy |
Mar-01-21 | Initiated | Raymond James | Outperform |
Mar-01-21 | Initiated | SVB Leerink | Outperform |
View All
Landos Biopharma Inc Stock (LABP) Latest News
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
Zacks Investment Research
Nasdaq Turns Higher; Akanda Shares Plunge
Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Crude Oil Moves Higher; US New Home Sales Fall In February
Benzinga
US Stocks Down; Chicago Fed National Activity Index Rises In February
Benzinga
Landos Biopharma Inc Stock (LABP) Financials Data
Landos Biopharma Inc (LABP) Net Income 2024
LABP net income (TTM) was -$21.93 million for the quarter ending December 31, 2023, a +44.15% increase year-over-year.
Landos Biopharma Inc (LABP) Cash Flow 2024
LABP recorded a free cash flow (TTM) of -$20.48 million for the quarter ending December 31, 2023, a +55.27% increase year-over-year.
Landos Biopharma Inc (LABP) Earnings per Share 2024
LABP earnings per share (TTM) was -$3.46 for the quarter ending December 31, 2023, a +64.55% growth year-over-year.
About Landos Biopharma Inc
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
Cap:
|
Volume (24h):